FRANCISCO CIRUELA

Neuropharmacology and Pain

ORCID Research Profile

FRANCISCO CIRUELA

Position: Professor of Pharmacology

Research team

 

Victor Fernandez Dueñas

Associate professor

vfernandez (at) ub.edu

 

Maria Laura Cuffi Cheliz

Associate Professor

lcuffi (at) ub.edu

 

Xavier Morato Arus

Post-doctoral researcher

xavmoratoar (at) ub.edu

 

Ester Aso

Principal investigator

ester.aso (at) ub.edu

 

Marc Lopez Cano

Early stage researcher

marclopezcano (at) ub.edu

 

Marta Valle Leon

Early stage researcher

marta.vleon (at) gmail.com

 

Josep Argerich

Early stage researcher

 

Héctor Godoy Marín

Early stage researcher

hectorgodoymarin13 (at) gmail.com

 

Kristoffer Sahlholm

Collaborator

kristoffer.sahlholm (at) ki.se

 

Salut Sánchez Rodriguez

Administrative and technical staff

salutsanchez (at) ub.edu

 

Sebastian Videla

Clinical Collaborator

svidela (at) bellvitgehospital.cat

 

Xavier Altafaj

Collaborator

xaltafaj (at) idibell.cat

Contact details

 

Dr. Francisco Ciruela

Department of Patologia i Terapèutica Experimental

Faculty of Medicine, Av. Feixa Llarga, s/n

08907 L’Hospitalet de Llobregat (Spain)

934024280

fciruela (at) ub.edu

www.ub.edu/neuropharmpain

Research Interests

 

The research conducted in our group is mainly focused on seeking new pharmacological strategies to reach an effective management of neurological, neuropsychiatric and pain diseases. Our aim consists of providing a deep mechanistic understanding of neurotransmitter receptors functioning which may help to design combined therapies or oligomer-tailored drugs in the near future. In addition, our interests include the development and implementation of novel biotechnological methodologies (e.g. fluorescence based biosensors, optopharmacology, etc.) that may eventually evolve into new tools for both the study and diagnostic of diseases.

Finally, our main goal is the translation of our results from the bench to the bedside and to clinical practice. Accordingly, to translate basic scientific findings into therapeutic interventions for patients we are also involved in clinical pharmacology studies, specially pharmacoepidemiological studies and clinical trials.

Current Research Lines

 

  • Adenosine and dopamine receptor-receptor interactions in the neurobiology of schizophrenia & Parkinson’s disease
  • GPCRs & ion channels oligomerization
  • The Parkinson’s disease-associated GPR37 receptor: a promising target for neurological diseases
  • Targeting the sigma-1 receptor: Pain and more
  • GPCR Optopharmacology

Technologies / methods

 

  • Molecular and in cell studies: Drug design, GPCR structure, BRET, FRET, TR-FRET, biosensors, real-time single cell FRET, NanoBRET, fluorescent ligands, optopharmacology, primary neuronal cultures and brain slices.
  • In animal studies: Pharmacological and genetic animal models for neurological diseases and pain (i.e. Parkinson disease, Alzheimer disease, schizophrenia and Pain). Knock-out animals for GPCRs.
  • In human studies: Peripheral and central biomarkers for neurological diseases.

Highlighted publications

 

· Font, J., López-Cano, M., Notartomaso, S., Scarselli, P., Di Prieto, P., Bresolí-Obach, R., Battaglia, G., Malhaire, F., Rovira, X., Catena, J., Giraldo, J., Pin, J.P., Fernández-Dueñas, V., Goudet, C., Nonell, S., Nicoletti, F., Llebaria, A., Ciruela, F. (2017). Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator. eLife 6, e23545.

 

· Sokolina, K., Kittanakom, S., Snider, J., Kotlyar, M., Maurice, P., Gandía, J., Benleulmi-Chaachoua, A., Tadagaki, K., Wong, V., Malty, R.H., Deineko, V., Aoki, H., Amin, S., Riley, L., Yao, Z., Morató, X., Rahmati, S., Kobayashi, H., Menéndez, J., Auerbach, D., Angers, S., Pržulj, N., Bouvier, M., Babu. M., Ciruela, F., Jockers, R., Jurisica, I. & Stagljar, I. (2017). Systematic interactome mapping of protein-protein interactions for clinically-relevant human GPCRs. Molecular Systems Biology 13 (3), 918.

 

· Ciruela, F., Fernández-Dueñas, V. & Jacobson, K.A.x (2015). Lighting up G protein-coupled purinergic receptors with engineered fluorescent ligands. Neuropharmacology 98, 58-67.

 

· García-Negredo, G., Soto, D., Llorente, J., Morató, X., Galenkamp, K.M.O., Gómez-Soler, M., Fernández-Dueñas, V., Adelman, J.P., Shigemoto, R., Fukozawa, Y., Luján, R. & Ciruela, F. (2014). Co-assembly and coupling of mGlu5 receptors and SK2 channels. Journal of Neuroscience 34 (44), 14793–14802.

 

· Ciruela, F., Vilardaga, J.P. & Fernández-Dueñas. V. (2010). Lighting up multiprotein complexes: lessons from GPCR oligomerization. Trends in Biotechnology 28 (8), 407-415.